Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAetna plerixafor Coverage & Prior Auth | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0779

    Plerixafor

    Customize your policy alerts

    Sign up for Aetna Policy 0779 alerts

    Get alerted when Policy 0779 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, dosing information, coding, and background evidence for plerixafor (Mozobil or generic) used to mobilize hematopoietic stem cells prior to autologous transplantation, primarily affecting clinicians and billing staff managing patients with non-Hodgkin lymphoma or multiple myeloma.

    Policy Summary
    PayerAetna
    PolicyPlerixafor
    Policy CodePolicy 0779
    Change TypeNo material changes
    Effective DateMar 20, 2009
    Last ReviewJan 9, 2024
    Next Review DateMar 28, 2024
    Key ActionObtain prior authorization and document that plerixafor will be used after G-CSF for stem cell mobilization in MM or NHL.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4 daysmax consecutive days
    20 mg/mLvial concentration
    0.24 mg/kgstandard dosing
    >=2 x10^6trial target collection
    CPB 0055related policy

    Coverage Criteria for Plerixafor (Mozobil)

    inv-01: Initial Approval — Hematopoietic Stem Cell Mobilization — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Initial approval criteria: The requested medication will be used to mobilize hematopoietic stem cells for collection prior to transplantation; and the requested medication will be administered after the member has received a granulocyte-colony stimulating factor (G-CSF) (e.g., filgrastim) or chemo-mobilization; and the requested medication will not be used beyond 4 consecutive days or after completion of stem cell harvest/apheresis.

    inv-02: Continuation of Therapy — continuation criteria node

    Continuation of plerixafor (Mozobil) injection therapy is medically necessary for all members (including new members) who meet all initial medical necessity selection criteria.

    Includes member transfers/new members who meet initial criteria.

    inv-03: FDA-approved indication — adults with MM or NHL — Covered when ALL of the following are met:

    Policy Summary
    PayerAetna
    PolicyPlerixafor
    Policy CodePolicy 0779
    Change TypeNo material changes
    Effective DateMar 20, 2009
    Last ReviewJan 9, 2024
    Next Review DateMar 28, 2024
    Key ActionObtain prior authorization and document that plerixafor will be used after G-CSF for stem cell mobilization in MM or NHL.
    SourceLink
    On This Page
    Coverage Criteria for Plerixafor (Mozobil)Coding and BillingProvider Responsibilities, Prior Authorization, and DocumentationDosing Regimens and Supported CombinationsLine of Therapy ContextBiomarker and Laboratory ThresholdsDefinitionsBackground and Evidence SummaryRevision History

    Covered when ALL of the following are met:

    FDA-approved use: Patient is an adult with multiple myeloma (MM) or non-Hodgkin lymphoma (NHL)

    Based on pivotal randomized trials demonstrating improved CD34+ yields and collection outcomes with plerixafor + G-CSF versus placebo + G-CSF (Studies 1 and 2).

    Combination therapy: Plerixafor will be administered in combination with G-CSF per the approved regimen (e.g., plerixafor 0.24 mg/kg SC given the evening prior to apheresis with G-CSF 10 μg/kg daily)

    Trials used G-CSF 10 μg/kg daily prior to and during apheresis; dosing and timing per FDA-approved regimen.

    inv-04: Remobilization or inadequate prior mobilization (non-hematologic or pediatric reports) — Considered medically reasonable when ALL apply

    Considered medically reasonable (case series and small studies) when ALL of the following apply:

    Prior mobilization failure: Documented prior mobilization failure or insufficient CD34+ collection with standard mobilization (G-CSF ± chemotherapy)

    Published series report successful remobilization when plerixafor is added after prior mobilization attempts.

    Patient population: Patients with non-hematologic diseases requiring stem cell collection or heavily pre-treated pediatric solid tumor patients where standard mobilization failed

    Evidence largely from small case series and reports; use reserved for remobilization scenarios.

    inv-05: Investigational or adjunctive oncology uses — Not established/experimental

    Not established/experimental — use only in clinical trials or with strong justification:

    AML/ALL/CLL/CML use: Use of plerixafor to chemosensitize or to mobilize leukemic blasts in AML, ALL, CLL, or CML is investigational; preliminary studies show biological activity and mixed clinical signals, and plerixafor may mobilize malignant cells posing risk of contaminating apheresis products.

    Preliminary phase I/II data exist but require validation; leukemia mobilization is contraindicated for standard harvests.

    Solid tumors and other indications: Use of plerixafor as an adjunct to radiotherapy/chemoradiation (e.g., glioblastoma, cervical cancer), to treat antibody-mediated rejection, or as an antiviral based on screening studies is investigational and requires further study.

    Evidence limited to early-phase trials, preclinical studies, or in-silico screens.

    inv-06: Other Indications — investigational/insufficient evidence

    Plerixafor use outside approved stem cell mobilization indications is described in multiple early-phase studies and preclinical reports; coverage is contingent on robust clinical evidence and is generally considered investigational.

    Glioblastoma/Glioma: Preclinical data and early-phase trials suggest CXCR4 antagonism (plerixafor) can reduce tumor-associated macrophage influx after irradiation, reduce post-irradiation tumor blood flow, and may improve local tumor control; phase I studies with bevacizumab show tolerability and measurable tumor/CSF penetration but require further trials.evidence limited to preliminary studies
    Light-chain (AL) Amyloidosis — HPC mobilization: Single-center series report combined G-CSF/plerixafor mobilization as safe and effective with high median CD34+ yields and low peri-mobilization morbidity; evidence requires validation in larger studies.single-center observational evidence
    Lung cancer (SCLC/NSCLC): Preclinical rationale exists for targeting CXCR4 to disrupt tumor–stroma interactions and sensitize tumors to cytotoxic therapy; clinical data are limited to preclinical and review-level evidence.preclinical/review-level
    Sickle cell disease (HPC mobilization): Preclinical and limited clinical data support plerixafor mobilization without G-CSF to avoid vaso-occlusion; dosing escalation may increase fold-change in PB CD34+ counts but absolute counts vary—further study needed for gene therapy applications.early-stage/ongoing trials
    WHIM syndrome: Phase I and small long-term studies indicate low-dose plerixafor can correct neutropenia and reduce infections; data are preliminary but suggest mechanism-based potential and need larger studies for long-term safety and efficacy.small nonrandomized trials
    Renal ischemia/acute kidney injury: Animal models show CXCR4 antagonism with plerixafor reduces renal injury and inflammatory markers after ischemia-reperfusion; evidence limited to preclinical models.preclinical only
    Combined mobilization (plerixafor + bortezomib/cyclophosphamide): Case reports/series indicate adding plerixafor to bortezomib and cyclophosphamide can substantially increase CD34+ collection in difficult-to-mobilize patients; data are limited and observational.case reports/series
    Malaria/Antiparasitic hypothesis and antiviral repurposing: In-silico docking and high-throughput repurposing screens have identified plerixafor as a potential hit for plasmepsin inhibition or viral channel-blocking activity; these are hypothesis-generating and lack in-vivo validation.in-silico/screening only

    Aetna considers plerixafor (Mozobil) experimental and investigational for all indications other than mobilization for autologous transplantation in non‑Hodgkin lymphoma and multiple myeloma because effectiveness for other uses has not been established.

    Plerixafor is not intended for hematopoietic stem cell mobilization and harvest in patients with leukemia because it may mobilize leukemic cells and contaminate the apheresis product; this contraindication can lead to denial of coverage for leukemia indications.

    Most other reported indications for plerixafor are supported only by preclinical data, early‑phase clinical reports, case series, or single‑center observational studies and therefore require further clinical trials and validation; as such they are effectively excluded from routine coverage.

    Use of plerixafor for antibody‑mediated lung transplant rejection and as an antiviral for dengue or West Nile virus is not established; current reviews and screening studies identify these as emerging or hypothesis‑generating areas but provide insufficient evidence to support medical necessity.

    Several indications are supported only by in‑silico analyses, preclinical models, hypothesis‑generating reports, or very small early‑phase clinical studies (for example, malaria, post‑herpetic neuralgia, and various oncology settings); these uses remain investigational and require additional validation before they can be considered medically necessary.

    Coding and Billing

    Other related CPT codesCPT
    38205Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic
    38206Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
    38230Bone marrow harvesting for transplantation; allogeneic
    38232Bone marrow harvesting for transplantation; autologous
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
    38241Hematopoietic progenitor cell (HPC); autologous transplantation
    96372Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
    Covered HCPCS Codes if selection criteria metHCPCSCovered
    J2562Injection, plerixafor, 1 mg [Mozobil]
    Other related HCPCS codesHCPCS
    J1442Injection, filgrastim (G-CSF), excludes biosimilars, 1 microgram
    J1447Injection, tbo-filgrastim, 1 microgram [Granix, Neutroval]
    J2505Injection, pegfilgrastim, 6 mg
    J2506Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
    J2820Injection, sargramostim (GM-CSF), 50 mcg
    Q5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
    Q5111Injection, Pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg
    ICD-10 codes covered if selection criteria are metICD-10Covered
    C82.00
    C82.99
    C83.00 - C83.99Lymphosarcoma and related malignant tumors of lymphatic tissue
    C84.00 - C84.99Other malignant neoplasms of lymphoid and histiocytic tissue
    C88.4
    C88.8 - C90.32Malignant immunoproliferative diseases and multiple myeloma
    C91.40 - C91.42
    C96.0 - C96.9
    ICD-10 codes not covered for CPB-listed indications (experimental/non-covered)ICD-10Not Covered
    A90Dengue fever
    A91Dengue hemorrhagic fever
    A92.30 - A92.39West Nile virus infection
    C33 - C34Malignant neoplasm of trachea, bronchus, and lung
    C53.0 - C53.9Malignant neoplasm of cervix uteri
    C71.0 - C71.9Malignant neoplasm of brain [glioma]
    C91.00 - C91.02Acute lymphoblastic leukemia [ALL]
    D57.00 - D57.819Sickle-cell disorders
    D70.0 - D70.9Neutropenia [treatment or prophylaxis]
    inv-17: Minimum pre-apheresis peripheral blood CD34+ count for successful day 1 collection
    Minimum pre-apheresis PB CD34+20 cells/µL (minimum threshold correlated with successful day‑1 collection)
    Source contextDerived from Pusic et al. analysis correlating pre‑apheresis PB CD34+ with first‑day apheresis yield
    Clinical implicationPre‑apheresis PB CD34+ <20 cells/µL predicts low likelihood of successful day‑1 collection and may prompt remobilization strategies
    inv-18: CD34+ collection thresholds — examples cited
    Common collection targets≥2 x10^6 CD34+ cells/kg is a common minimum success threshold used in observational series and trials
    Higher trial targets (NHL)Study 1: ≥5 x10^6 CD34+ cells/kg collected within ≤4 aphereses (59% with plerixafor+G‑CSF vs 20% with placebo+G‑CSF)
    Higher trial targets (MM)Study 2: ≥6 x10^6 CD34+ cells/kg collected within ≤2 aphereses (72% with plerixafor+G‑CSF vs 34% with placebo+G‑CSF)
    Remobilization series exampleNon‑hematologic remobilization series: 85% achieved ≥2 x10^6 CD34+/kg after plerixafor+G‑CSF

    Provider Responsibilities, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for HCPCS J2562 (plerixafor, 1 mg) and associated injection/procedure codes when used for hematopoietic progenitor cell (HPC) mobilization prior to transplantation. Follow Aetna prior authorization processes and submit requests before therapy initiation.

    • Affected code: J2562 (Injection, plerixafor, 1 mg)
    • Related administration codes: 96372; harvest CPTs 38205, 38206, 38230, 38232, 38240, 38241
    • Policy reviewed: 01/09/2024; Effective: 03/20/2009
    Prior Authorization

    Prior Authorization for plerixafor (Mozobil)

    Plerixafor (Mozobil) is FDA-approved for use in combination with G-CSF for mobilization of hematopoietic stem cells in adults with multiple myeloma (MM) or non-Hodgkin lymphoma (NHL). Prior authorization should document the indication and planned use with G-CSF per the FDA regimen.

    • FDA indication: adults with MM or NHL in combination with G-CSF (Genzyme PI)
    • Document that plerixafor will be given per approved regimen (e.g., evening doses after G-CSF)
    • Evidence: phase 3 trials demonstrating improved CD34+ collection with plerixafor + G-CSF
    Note

    Plerixafor for HPC Mobilization (Amyloidosis)

    Plerixafor plus G-CSF has been used for HPC mobilization in light chain (AL) amyloidosis and reported as safe and effective in cohort studies; include this context in authorization requests when mobilization is for AL amyloidosis prior to transplant.

    • AL amyloidosis data: cohort of 53 patients with good collection yields and acceptable toxicity (Badar et al., 2019)
    • These findings require validation in larger controlled studies but may support individual clinical justification
    Documentation Required

    G-CSF or Chemo-mobilization Prerequisite

    Plerixafor must be administered after the member has received G-CSF or chemo-mobilization prior to authorization; requests should state prior mobilization regimen and timing relative to planned plerixafor dosing.

    • Prerequisite: G-CSF (e.g., filgrastim) or chemo-mobilization completed before plerixafor per policy criteria
    • Typical regimen: G-CSF daily for 4 days prior to first plerixafor dose (per FDA studies)
    Step Therapy

    Step Therapy Context

    Step therapy context: evidence supports plerixafor plus G-CSF, particularly for patients who fail initial mobilization with G-CSF ± chemotherapy. No explicit step-therapy sequence is defined in this policy, but prior mobilization attempts and rationale should be documented.

    • Studies show lower failure rates with G-CSF + plerixafor versus G-CSF alone
    • Document prior mobilization attempts (dates, regimens, and outcomes) when applicable
    • No formal step sequence mandated by policy
    Note

    Mobilization Alternative in SCD

    Plerixafor has been explored as an alternative mobilization strategy in sickle cell disease (SCD) due to the vaso-occlusive risk associated with G-CSF; include this consideration and any relevant trial identifiers in authorization notes.

    • Preclinical and early clinical data suggest plerixafor may mobilize HPCs without vaso-occlusion seen with G-CSF
    • Clinical trials in SCD (e.g., NCT02193191) are ongoing — use in SCD should be justified with supporting data
    Documentation Required

    Required Clinical Documentation

    Required clinical documentation: Prior authorization requests must include indication (MM, NHL, or specific off-label justification such as AL amyloidosis), planned combination with G-CSF per regimen, prior mobilization attempts and outcomes, and intended dosing schedule for harvest.

    • Indication and transplant intent (mobilization for collection prior to transplantation)
    • Confirmation that G-CSF or chemo-mobilization was given prior to plerixafor
    • Details of prior mobilization failures (if any) including CD34+ yields and dates
    • Planned plerixafor dosing schedule and duration (not to exceed 4 consecutive days or beyond completion of harvest)
    Documentation Required

    Trial Dosing and Pharmacokinetic Documentation

    Trial dosing and pharmacokinetic documentation: clinical trial regimens and pharmacokinetic data (e.g., 0.24 mg/kg evening dosing in phase 3 trials; PK/CSF/tissue levels in early glioma studies) may be referenced to support dosing rationale — include trial details when relevant.

    • Phase 3 studies used plerixafor 0.24 mg/kg given each evening prior to apheresis after G-CSF priming
    • Early-phase glioma studies report higher dose ranges (example: 320 µg/kg) with PK sampling — include such data only when supporting investigational use
    Documentation Required

    References to Prescribing Information and Clinical Guidelines

    References that should be included or cited in authorization/supporting documentation: Genzyme (Mozobil) prescribing information, NCCN Drugs & Biologics Compendium, HCT and IMWG guidelines, and key clinical studies showing efficacy of plerixafor + G-CSF.

    • Genzyme Corporation. Mozobil (plerixafor) Prescribing Information (latest revision)
    • NCCN Drugs & Biologics Compendium — Plerixafor (January 2023)
    • IMWG and HCT consensus/guidelines and pivotal clinical trials (Pusic 2008; Genzyme Phase 3 studies)
    Denial Risk

    Indication-Based Denial Risk, Investigational Use, and Contraindication (Leukemia)

    Indication-based denial risk and investigational use: Requests for indications other than mobilization prior to transplantation (or indications listed as appropriate in policy) are subject to denial as experimental/investigational. Use in leukemia is contraindicated due to risk of mobilizing leukemic cells and potential contamination of the apheresis product.

    • Experimental/Investigational indications include leukemia, many solid tumors, SCD (outside trial context), and others listed in the policy
    • Contraindication: leukemia — plerixafor may mobilize leukemic cells and is not intended for HSC mobilization in leukemia patients
    • Policy denials may be issued when requested use is outside approved/medically necessary criteria
    Note

    No Explicit Denial Triggers Stated

    Administrative note: The policy does not list explicit single denial triggers beyond the stated coverage criteria; Clinical Policy Bulletins (CPBs) do not guarantee coverage. Adjudication follows standard Aetna medical necessity review processes.

    • No explicit additional denial triggers are specified in this CPB
    • Coverage determinations are made case-by-case and prior authorization approval does not guarantee payment

    Dosing Regimens and Supported Combinations

    RegimenIndication / SettingTiming / NotesCoverage status
    Plerixafor 0.24 mg/kg subcutaneously (given evening prior to apheresis) plus G-CSF (e.g., G-CSF 10 µg/kg daily)
    Stem cell mobilization for autologous transplantation in adults with multiple myeloma (MM) or non-Hodgkin lymphoma (NHL)
    Plerixafor administered each evening prior to planned apheresis after daily G-CSF for at least 4 days; dosing and schedule per pivotal trials (approximately 11 hours prior to apheresis)
    Covered
    RegimenIndication / SettingTiming / NotesCoverage status
    Single‑agent plerixafor (subcutaneous) with apheresis performed ~4–6 hours after dose
    Investigational mobilization approach for patients where G-CSF/chemomobilization is contraindicated or in pediatric/solid tumor contexts (case series and small studies)
    Small series used single‑agent subcutaneous plerixafor followed by apheresis 6 hours later; further study recommended to optimize route, timing, and yield
    Experimental
    RegimenIndication / SettingTiming / NotesCoverage status
    Plerixafor 320 µg/kg subcutaneously on days 1–21 plus bevacizumab 10 mg/kg IV on days 1 and 15 of each 28‑day cycle
    Phase I dose‑escalation regimen evaluated in recurrent high‑grade glioma (recurrent HGG) patients
    Part 1 used a 3x3 escalation to a maximum tolerated dose (plerixafor 320 µg/kg days 1–21); plasma, CSF and tumor penetration assessed; no DLTs at MTD reported
    Experimental
    RegimenIndication / SettingTiming / NotesCoverage status
    Plerixafor administered in combination with G‑CSF and/or added to regimens containing bortezomib and cyclophosphamide
    Used in difficult‑to‑mobilize patients, including dialysis‑dependent multiple myeloma and other case‑series populations where prior mobilization yielded low CD34+ counts
    Case reports/series describe adding plerixafor to prior regimens (e.g., bortezomib + cyclophosphamide) to markedly increase CD34+ yields (one report noted a 6‑fold increase); evidence is limited to small observational reports
    Experimental

    Line of Therapy Context

    inv-42: first-line | salvage — 1 top-level node

    Use for PBSC mobilization: Primarily used as part of first-line mobilization regimen in combination with G-CSF (per FDA) or as salvage/remobilization when initial mobilization fails.

    Trials support both first-line efficacy and improved remobilization outcomes.

    inv-43: salvage — 1 top-level node

    Recurrent HGG trial: Phase I trial combined plerixafor + bevacizumab in recurrent high-grade glioma with a 3x3 dose escalation to an MTD of plerixafor 320 µg/kg days 1–21 plus bevacizumab 10 mg/kg IV on days 1 and 15; no DLT at MTD and tolerable safety profile.

    Primarily a salvage/experimental setting.

    Biomarker and Laboratory Thresholds

    inv-44: CXCR4 / CXCL12 pathway — biomarker context
    PathwayCXCR4 / CXCL12 (SDF‑1α) chemokine axis mediates HSC trafficking and tumor‑associated macrophage (TAM) recruitment
    Mechanistic roleCXCR4/CXCL12 interaction anchors HSCs to marrow and drives TAM influx after irradiation (relevant to MERT strategies)
    Therapeutic rationaleBlocking CXCR4 (e.g., plerixafor) disrupts CXCL12 binding, mobilizes HSCs, and may reduce TAM accumulation to enhance radiotherapy response
    inv-45: sMET, sVEGFR1, CD34+, CD8-T cells, plasma SDF1α, PlGF — biomarkers mentioned in trials/reports
    Biomarkers observed in glioma studyPre‑treatment plasma sMET and sVEGFR1 correlated with PFS; changes in CD34+ progenitor cells and CD8 T‑cells correlated with OS
    Plasma pharmacodynamicsPlerixafor + bevacizumab induced rapid, persistent increases in plasma SDF1α and PlGF in the phase I glioma study
    Context and sourcesReported in phase I glioma trial with PK/PD sampling and referenced compendia/literature

    Definitions

    inv-36: Mobilization — definition of moving HSCs from bone marrow into peripheral blood for collection
    DefinitionMobilization: the process of moving hematopoietic stem cells (HSCs) from bone marrow into peripheral blood for collection (apheresis), commonly using G‑CSF and agents like plerixafor)
    Typical use casePerformed prior to autologous transplantation to obtain peripheral blood stem cells for infusion
    Relation to CXCR4/CXCL12Mobilization strategies often target CXCR4/CXCL12 interactions to release HSCs from marrow niches
    inv-37: Plerixafor (Mozobil) — CXCR4 antagonist mechanism summary
    Mechanism summaryPlerixafor (Mozobil) is a CXCR4 chemokine receptor antagonist that blocks binding of SDF‑1α (CXCL12) to CXCR4, disrupting marrow anchoring of HSCs and facilitating mobilization into peripheral blood
    Indication noteApproved in combination with G‑CSF for mobilization of HSCs in MM and NHL (FDA; Genzyme prescribing information)
    Safety considerationsPrescribing information lists warnings including tumor cell mobilization in leukemia, hypersensitivity, splenic rupture, and hematologic effects
    inv-38: Successful mobilization — definition and common CD34+ thresholds (e.g., >=2 x10^6 CD34+ cells/kg)
    Definition of successful mobilizationAchievement of a target CD34+ cell dose for transplantation (commonly ≥2 x10^6 CD34+ cells/kg); trials have used higher targets such as ≥5 or ≥6 x10^6 CD34+ cells/kg depending on graft goals)
    Operational benchmarksPhase 3 studies reported proportions reaching ≥5 x10^6/kg (NHL) or ≥6 x10^6/kg (MM) within limited aphereses when using plerixafor+G‑CSF
    Clinical relevanceSuccessful mobilization correlates with timely engraftment; pre‑apheresis PB CD34+ and achieved/kg dose guide adequacy for transplant
    inv-39: MERT — concept reference related to SDF-1/CXCR4 pathway modulation
    ConceptMERT (macrophage exclusion after radiation therapy): strategy to enhance tumor response and protect normal tissue by blocking TAM accumulation via the SDF‑1/CXCR4 pathway
    Relation to CXCR4 antagonismPreclinical and early clinical data suggest CXCR4 blockade (e.g., plerixafor) can prevent post‑irradiation TAM influx and improve local tumor control
    Evidence statusPreliminary findings require validation in well‑designed clinical trials
    inv-40: WHIM syndrome — rare congenital CXCR4 gain-of-function syndrome definition
    DefinitionWHIM syndrome: rare congenital immunodeficiency caused by autosomal dominant gain‑of‑function CXCR4 mutations (warts, hypogammaglobulinemia, infections, myelokathexis)
    PathophysiologyCXCR4 carboxy‑terminus truncation leads to neutropenia and retention of neutrophils in marrow (myelokathexis)
    Plerixafor relevanceSmall studies show plerixafor can mobilize leukocytes and correct neutropenia in WHIM at low intermittent doses with favorable tolerability
    inv-41: Plerixafor (Mozobil) — prescribing information citation (Genzyme, revised Aug 2020)
    Prescribing informationGenzyme Corporation. Mozobil (plerixafor) injection, prescribing information; revised August 2020
    Regulatory statusMozobil is indicated with G‑CSF for mobilization of HSCs for autologous transplantation in MM and NHL
    Key safety warningsPI includes warnings: tumor cell mobilization in leukemia, hypersensitivity/anaphylaxis, splenic rupture, hematologic effects; common adverse reactions listed

    Background and Evidence Summary

    Plerixafor (Mozobil) is a CXCR4 antagonist that disrupts SDF‑1α/CXCR4 interactions to mobilize hematopoietic stem cells (HSCs) into the peripheral blood for collection and subsequent autologous transplantation. It is FDA‑approved for use in combination with granulocyte‑colony stimulating factor (G‑CSF) in adults with multiple myeloma or non‑Hodgkin lymphoma and is supplied for subcutaneous injection; pivotal trials and the prescribing information describe its administration approximately 11 hours before apheresis and use for up to 4 consecutive days in the mobilization setting.

    Revision History

    2024-01-09policy_reviewLatest

    Policy reviewed by Aetna (last review date recorded).

    2009-03-20effective_date

    Policy became effective for plerixafor coverage criteria and prior authorization processes.

    2024-03-28next_review_target

    Target date set for the next policy review (next review).